Pivekimab sunirine in combination with venetoclax and azacitidine for CD123-positive AML

The synergetic mechanism of pivekimab sunirine and venetoclax and its potential for treating AMLПодробнее

Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AMLПодробнее

Novel combinations being explored in AML using an HMA-venetoclax backboneПодробнее

Update on IMGN632: CD123 antibody-drug conjugate for R/R AML and BPDCNПодробнее

AML: Managing AEs With Venetoclax + AzacitidineПодробнее

Naval Daver - Pivekimab sunirine (PVEK, IMGN632) triplet with Azacitidine and VenetoclaxПодробнее

Advances in targeted approaches for AML: magrolimab & pivekimab sunirineПодробнее

IMGN632 plus venetoclax and/or azacitidine for patients with CD123-positive AMLПодробнее

IMGN632 is efficacious with venetoclax plus azacitidine in AML modelsПодробнее

allo-SCT improves survival following venetoclax and azacitidine therapy in AMLПодробнее

Treating patients with poor-risk cytogenetics with venetoclax and HMAsПодробнее

AML: Optimizing Selection and Use of Venetoclax + AzacitidineПодробнее

Venetoclax + Azacitidine in Frontline AML ManagementПодробнее

Pevonedistat, venetoclax and azacitidine for older AML patientsПодробнее

Predictors of poor response to azacitidine, venetoclax, and magrolimab in TP53-mutated AMLПодробнее

Christophe Willekens, MD: Reduced Venetoclax and Azacitidine in AMLПодробнее

SELECT-AML-1: tamibarotene with venetoclax and azacitidine in patients with RARA-positive AMLПодробнее

The promise of CD123-directed immunotherapy in AML and agents of interestПодробнее

Investigating the safety & efficacy of magrolimab, azacitidine & venetoclax in patients with AMLПодробнее